D2B3 Overview
- Year Founded
-
2024
- Status
-
Private
- Employees
-
3
- Latest Deal Type
-
Accelerator/Inc
- Latest Deal Amount
-
$480K
- Investors
-
6
D2B3 General Information
Description
Operator of a pre-clinical biotechnology platform intended to advance drug delivery to the brain and central nervous system. The company offers proprietary technology that transiently and specifically opens the blood-brain barrier, enabling the targeting of CNS diseases with high efficacy, and providing a versatile, plug-and-play approach for most drugs and therapeutic classes.
Contact Information
Website
www.d2b3.bioCorporate Office
- 101 College Street
- Suite 210
- New Haven, CT 06510
- United States
Corporate Office
- 101 College Street
- Suite 210
- New Haven, CT 06510
- United States
D2B3 Timeline
D2B3 Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Accelerator/Incubator | 07-Apr-2025 | $480K | Completed | Pre-Clinical Trials | ||
| 5. Early Stage VC | 01-Jan-2025 | Completed | Pre-Clinical Trials | |||
| 4. Accelerator/Incubator | 24-Sep-2024 | Completed | Pre-Clinical Trials | |||
| 3. Accelerator/Incubator | 26-Jul-2024 | Completed | Product Development | |||
| 2. Accelerator/Incubator | 01-Jun-2024 | $400K | Completed | Product Development | ||
| 1. Seed Round | 01-Jan-2022 | $400K | $400K | Completed | Product Development |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
D2B3 Comparisons
Industry
Financing
Details
D2B3 Competitors (2)
One of D2B3’s 2 competitors is Aerska, a Venture Capital-Backed company based in Dublin, Ireland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aerska | Venture Capital-Backed | Dublin, Ireland | ||||
| Denali Therapeutics | Formerly VC-backed | South San Francisco, CA |
D2B3 Signals
D2B3 Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Creative Destruction Lab | Accelerator/Incubator | |||
| Connecticut Innovations | Venture Capital | Minority | ||
| Mission BioCapital | Venture Capital | Minority | ||
| MassBio | Accelerator/Incubator | |||
| IndieBio | Accelerator/Incubator |
D2B3 FAQs
-
When was D2B3 founded?
D2B3 was founded in 2024.
-
Where is D2B3 headquartered?
D2B3 is headquartered in New Haven, CT.
-
What is the size of D2B3?
D2B3 has 3 total employees.
-
What industry is D2B3 in?
D2B3’s primary industry is Biotechnology.
-
Is D2B3 a private or public company?
D2B3 is a Private company.
-
What is D2B3’s current revenue?
The current revenue for D2B3 is .
-
How much funding has D2B3 raised over time?
D2B3 has raised $980K.
-
Who are D2B3’s investors?
Creative Destruction Lab, Connecticut Innovations, Mission BioCapital, MassBio, and IndieBio are 5 of 6 investors who have invested in D2B3.
-
Who are D2B3’s competitors?
Aerska and Denali Therapeutics are competitors of D2B3.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process